Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination

Background Development of high avidity, broadly neutralizing antibodies (Abs) is a priority after vaccination against rapidly evolving, widely disseminated viruses like human norovirus. After vaccination with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked early, with no increase in titer following a second vaccine dose. Methods Blockade Ab relative avidity was evaluated by measuring the slope of blockade Ab neutralization curves. Results Blockade Ab avidity to the GI.1 vaccine component peaked at day 35 (7 days after dose 2). Avidities to heterotypic genogroup I VLPs were not sustained at day 35 after vaccination or GI.1 infection, as measured from archived sera. Only secretor-positive participants maintained high avidity blockade Ab to GI.1 at day 180. Avidity to the GII.4c vaccine component peaked at day 7, remained elevated through day 180, and was not secretor dependent. Avidity to an immunologically novel GII.4 strain VLP correlated with preexisting Ab titer to an ancestral strain Epitope A. Conclusions Host genetics and pre-exposure history shape norovirus vaccine Ab responses, including blockade Ab avidity. Avidity of potentially neutralizing Ab may be an important metric for evaluating vaccine responses to highly penetrant viruses with cross-reactive serotypes.

[1]  F. Baehner,et al.  Vaccines against norovirus: state of the art trials in children and adults. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  D. Graham,et al.  Replication of human noroviruses in stem cell–derived human enteroids , 2016, Science.

[3]  R. Walker,et al.  Status of vaccine research and development for norovirus. , 2016, Vaccine.

[4]  Sachiko Ozawa,et al.  Global Economic Burden of Norovirus Gastroenteritis , 2016, PloS one.

[5]  Chaim A. Schramm,et al.  Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody , 2016, Cell.

[6]  J. Buesa,et al.  Characterisation of a household norovirus outbreak occurred in Valencia (Spain) , 2016, BMC Infectious Diseases.

[7]  A. Chakraborty,et al.  Affinity Inequality among Serum Antibodies That Originate in Lymphoid Germinal Centers , 2015, PloS one.

[8]  D. Montefiori,et al.  Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies , 2015, Nature Communications.

[9]  D. Burton,et al.  Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies , 2015, PLoS pathogens.

[10]  Lijuan Yuan,et al.  Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives. , 2015, Future virology.

[11]  M. Beltramello,et al.  Serum Immunoglobulin A Cross-Strain Blockade of Human Noroviruses , 2015, Open forum infectious diseases.

[12]  D. Graham,et al.  Serological Correlates of Protection against a GII.4 Norovirus , 2015, Clinical and Vaccine Immunology.

[13]  T. Pierson,et al.  Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. , 2015, Virology.

[14]  D. Graham,et al.  Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. , 2015, The Journal of infectious diseases.

[15]  Martin T. Ferris,et al.  Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial , 2015, PLoS medicine.

[16]  J. Vinjé,et al.  Noroviruses: epidemiology, immunity and prospects for prevention. , 2015, Future microbiology.

[17]  T. Pierson,et al.  A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. , 2015, Progress in molecular biology and translational science.

[18]  J. Treanor,et al.  A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. , 2014, The Journal of infectious diseases.

[19]  H. Uusi-Kerttula,et al.  High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children. , 2014, The Journal of infectious diseases.

[20]  S. Wallet,et al.  Enteric bacteria promote human and mouse norovirus infection of B cells , 2014, Science.

[21]  M. Beltramello,et al.  Particle Conformation Regulates Antibody Access to a Conserved GII.4 Norovirus Blockade Epitope , 2014, Journal of Virology.

[22]  M. Beltramello,et al.  Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. , 2013, The Journal of infectious diseases.

[23]  L. Svensson,et al.  Host Genetic Factors Affect Susceptibility to Norovirus Infections in Burkina Faso , 2013, PloS one.

[24]  Larissa B. Thackray,et al.  A Mouse Model for Human Norovirus , 2013, mBio.

[25]  E. Cromwell,et al.  Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans , 2013, PLoS neglected tropical diseases.

[26]  Antonio Lanzavecchia,et al.  Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.

[27]  R. Baric,et al.  Emergence of a Norovirus GII.4 Strain Correlates with Changes in Evolving Blockade Epitopes , 2012, Journal of Virology.

[28]  R. Baric,et al.  Norovirus Immunity and the Great Escape , 2012, PLoS pathogens.

[29]  M. Beltramello,et al.  Immunogenetic Mechanisms Driving Norovirus GII.4 Antigenic Variation , 2012, PLoS pathogens.

[30]  R. Purcell,et al.  Chimpanzees as an animal model for human norovirus infection and vaccine development , 2010, Proceedings of the National Academy of Sciences.

[31]  R. Baric,et al.  Norovirus GII.4 Strain Antigenic Variation , 2010, Journal of Virology.

[32]  D. Graham,et al.  Serological correlate of protection against norovirus-induced gastroenteritis. , 2010, The Journal of infectious diseases.

[33]  L. Svensson,et al.  Norovirus Gastroenteritis Outbreak with a Secretor-independent Susceptibility Pattern, Sweden , 2010, Emerging infectious diseases.

[34]  R. Johnston,et al.  Heterotypic Humoral and Cellular Immune Responses following Norwalk Virus Infection , 2009, Journal of Virology.

[35]  G. Air,et al.  Antibody quantity versus quality after influenza vaccination. , 2009, Vaccine.

[36]  Reem Abu Mallouh,et al.  The G428A Nonsense Mutation in FUT2 Provides Strong but Not Absolute Protection against Symptomatic GII.4 Norovirus Infection , 2009, PloS one.

[37]  D. Fremont,et al.  The structural immunology of antibody protection against West Nile virus , 2008, Immunological reviews.

[38]  D. Fremont,et al.  Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. , 2008, Cell host & microbe.

[39]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[40]  R. Baric,et al.  Mechanisms of GII.4 Norovirus Persistence in Human Populations , 2008, PLoS medicine.

[41]  R. Baric,et al.  Characterization of the homo‐ and heterotypic immune responses after natural norovirus infection , 2005, Journal of medical virology.

[42]  G. Air,et al.  Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. , 2005, Vaccine.

[43]  Xi Jiang,et al.  Human susceptibility and resistance to Norwalk virus infection , 2003, Nature Medicine.

[44]  R. Baric,et al.  Binding of Norwalk Virus-Like Particles to ABH Histo-Blood Group Antigens Is Blocked by Antisera from Infected Human Volunteers or Experimentally Vaccinated Mice , 2002, Journal of Virology.

[45]  STATUS OF IN , 2000 .

[46]  J. Moore,et al.  An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. , 1997, AIDS research and human retroviruses.

[47]  R. Cox,et al.  Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. , 1995, Vaccine.